Good post.
Patients receiving the treatment had significant dose-and time-dependent reduction of amyloid beta plaque, while patients in the control arm of the studies had no reduction of amyloid beta plaque.
Notice the article says nothing about improving the mental state of the patients, or reducing the memory loss. Amyloid beta is not the cause the problem Amyloid beta is the result of the real cause, and is produced by the body to solve the real problem.
I think they know that now, too. But at least they get to recoup their research money they wasted on their theory this way. FDA takes care of their own.
But the F.D.A. advisory committee, along with an independent think tank and several prominent experts — including some Alzheimer’s doctors who worked on the aducanumab clinical trials — said the evidence raised significant doubts about whether the drug is effective. They also said that even if aducanumab could slow cognitive decline in some patients, the benefit suggested by the evidence would be so slight that it would not outweigh the risk of swelling or bleeding in the brain that the drug caused in the trials.